Lilly Expands Gate Bioscience Alliance With New Target

Alliance expansion

Eli Lilly has expanded its alliance with Gate Bioscience, according to Biospace. The expansion adds one undisclosed target to the companies’ existing agreement and includes an option for a second target.

Biospace reported that Lilly and Gate first linked up in July 2025. The collaboration uses Gate’s Molecular Gate engine to address diseases with high unmet need. The newly added target has not been disclosed.

Agreement details

Biospace described the expansion as adding another $870M+ in biobucks. Its report characterized the move as Lilly doubling down on the Gate alliance to unlock a new drug class.

The added target joins the existing agreement, while the option provides for a possible second target. Biospace did not identify either target in the supplied report.

What the update confirms

The announcement extends an established relationship between Lilly and Gate rather than introducing a new collaboration. Biospace identified Gate’s Molecular Gate engine as the technology foundation for the companies’ work.

For pharmaceutical and biotech sales professionals following partnership activity, the update centers on the expanded scope of the existing alliance: one undisclosed target has been added, and a second remains optional.

Biospace’s report links the collaboration to diseases with high unmet need and notes that the original Lilly-Gate connection began in July 2025. Beyond the additional target and option, the supplied report does not disclose further target details.

Partnership milestone

The latest development marks a new milestone in the Lilly-Gate alliance. According to Biospace, the parties are building on their existing agreement through the added target, with an option for another.

The announcement keeps the focus on Gate’s Molecular Gate engine and Lilly’s continued participation in the collaboration. Biospace reported the financial figure as another $870M+ in biobucks.